These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8579073)
1. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion. DiMichele DM; Lasak ME; Miller CH Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073 [TBL] [Abstract][Full Text] [Related]
2. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion. Fernandez M; Yu T; Bjornson E; Luu H; Spotts G Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253 [TBL] [Abstract][Full Text] [Related]
3. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion. Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162 [TBL] [Abstract][Full Text] [Related]
4. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109 [TBL] [Abstract][Full Text] [Related]
5. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII). Goldsmith JC Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789 [TBL] [Abstract][Full Text] [Related]
6. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion. Morfini M; Messori A; Longo G Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791 [TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of factor VIII for surgery and major bleeding. Hay CR; Doughty HI; Savidge GF Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792 [TBL] [Abstract][Full Text] [Related]
8. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Deitcher SR; Tuller J; Johnson JA Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Schulman S; Varon D; Keller N; Gitel S; Martinowitz U Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997 [TBL] [Abstract][Full Text] [Related]
11. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII. Takedani H Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072 [TBL] [Abstract][Full Text] [Related]
12. Factor VIII concentrate for hemophilia: comparison of two heat-treated products. Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401 [TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of B-domain deleted recombinant factor VIII (ReFacto) stability during simulated continuous infusion administration. Neidhardt E; Koval R; Burke E; Warne N Haemophilia; 2005 Jul; 11(4):319-25. PubMed ID: 16011582 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D; Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442 [TBL] [Abstract][Full Text] [Related]
15. [The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump]. Rodríguez Bueno S; Montoro Ronsano JB; Martínez Sánchez B; Altisent Roca C; Tusell Puigvert JM Med Clin (Barc); 1991 Mar; 96(10):364-6. PubMed ID: 1904520 [TBL] [Abstract][Full Text] [Related]
16. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Auerswald G; Spranger T; Brackmann HH Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531 [TBL] [Abstract][Full Text] [Related]
17. Family issues in continuous infusion therapy with factor VIII. Manco-Johnson MJ Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S21-5. PubMed ID: 8735793 [TBL] [Abstract][Full Text] [Related]
18. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion. Frank RD; Kunz D; Wirtz DC Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729 [TBL] [Abstract][Full Text] [Related]
20. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]